NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

Excellent to hear from you as it was through you that I'd learned about the wild-type and mutated IDH in the first place, and your post confirms all that.

Additionally, L will almost certainly be the most effective option by far, for rGBM patients who weren't able to receive L at the time of initial diagnosis. (Kristyn's Dad is only here because of L.

To this point, another topic to consider is that should the control arm of the L trial that had crossed over, compare well statistically to the external control arms of other trials, that efficacy will be reflective of a positive outcome having used the original tumor from the initial diagnosis... and NOT, having used the tumor that had developed upon progression.

And many of us already know and have discussed ad nauseam about how, upon recurrence, GBM usually transitions to a more mesenchymal (works really well with DCVax-L) sub-type.

Therefore, it would be logical...
especially when comparing the success of other compassionate use types (such as Kat and Kristyn's dad) that had received L using their RECURRENT tumor (and not on the original tumor)...
that for a recurrent GBM patient, a positive prognosis is even more likely when DCVax-L is made with the recurrent tumor.